LIXTE BIOTECHNOLOGY HOLDINGS, INC. 8-K

What Happened Lixte Biotechnology Holdings, Inc. filed an 8-K (Item 1.01) disclosing that on Feb. 12–13, 2026 it entered into an Allocation Deed and a Consultancy Agreement with Liora Technologies Europe Ltd (its subsidiary) and consultant Sidney Bruan (listed as Sidney Braun in exhibits). Under the agreements, Bruan will join Liora’s board and serve as Liora’s Chief Executive Officer on a month-to-month consultancy basis and will report monthly to Lixte’s board.

Key Details

• Consultant: Sidney Bruan (also referenced as Sidney Braun in the exhibits).
• Payments: GBP 50,000 signing bonus (exclusive of VAT) and GBP 25,000 monthly retainer (exclusive of VAT).
• Term: Month-to-month consultancy unless terminated under the agreement.
• Responsibilities: setting Liora’s strategic vision, managing Liora’s executive team, and monthly operational reports to Lixte’s board.
• Allocation Deed sale provision: if Liora or a successor is sold, the Consultant is entitled to 20% of the net purchase price; Lixte must deliver a Valuation Notice after closing and disagreements can be resolved by a mutually agreed independent valuation expert.
• The company also furnished a press release under Regulation FD (Item 7.01).

Why It Matters This filing documents a material leadership and compensation arrangement for Lixte’s European subsidiary, assigning an experienced consultant as CEO with significant performance-linked economics (a potential 20% share of net sale proceeds). For investors, the deal may affect Lixte’s governance and future proceeds from any sale of Liora, and it creates an ongoing cash obligation (monthly retainer and signing bonus). The valuation and payout provisions define how any future sale-related payment to the consultant would be calculated and contested.